Recently, the realm of brain-computer interfaces (BCIs) has been abuzz with a series of encouraging developments. The Neuracle NEO system has achieved a groundbreaking milestone by securing the world's inaugural Class III medical device registration certificate specifically for invasive BCIs. Concurrently, Stair Medical has successfully concluded a strategic funding round, amassing 500 million yuan.

With the regulatory approval frameworks now clearly defined and significant strides being made in clinical applications, industry experts highlight that the BCI sector is undergoing a swift transformation from mere technological exploration to full-fledged commercialization. This shift is being propelled by a confluence of supportive policies, technological advancements, and capital influx. Firms operating across the entire industrial chain, from upstream suppliers to downstream service providers, are now entering a golden era characterized by rigorous product validation and aggressive market expansion. This momentum is propelling the industry into a new echelon, marked by enhanced quality and accelerated growth.